Workflow
ZUO LI YAO YE(300181)
icon
Search documents
佐力药业(300181) - 上海东方华银律师事务所关于浙江佐力药业股份有限公司2024年度股东大会的法律意见书
2025-05-15 11:28
上海东方华银律师事务所 2024 年度股东大会的法律意见书 致:浙江佐力药业股份有限公司 上海东方华银律师事务所(以下简称"本所")接受浙江佐力药业股份有限 公司(以下简称"贵司"或"公司")委托,就贵司召开 2024 年度股东大会的有 关事宜,根据《中华人民共和国公司法》(以下简称"《公司法》")、《上市公司股 东股东会规则》(以下简称"《股东会规则》")等法律、法规和其他规范性文件以 及《浙江佐力药业股份有限公司章程》(以下简称"《公司章程》")的有关规定, 出具本法律意见书。 为出具本法律意见书,本所律师审查了公司提供的本次股东大会的相关资料, 包括但不限于公司召开 2024 年度股东大会的通知、公司 2024 年度股东大会的议 程、议案及决议等文件资料,同时听取了公司董事会秘书就有关事实的陈述和说 明。公司已向本所作出保证和承诺,保证公司向本所提供的资料和文件均为真实、 准确、完整,无重大遗漏。 本所律师仅就本法律意见书出具日以前所发生的事实以及本所律师对有关 法律法规的理解发表法律意见。 本法律意见书仅供公司为本次股东大会之目的使用,不得用于其他任何目的。 本所同意本法律意见书作为公司本次股东大会公 ...
佐力药业(300181) - 2024年度股东大会决议公告
2025-05-15 11:28
证券代码:300181 证券简称:佐力药业 公告编号:2025-031 浙江佐力药业股份有限公司 2024年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没 有虚假记载、误导性陈述或重大遗漏。 特别提示: 1、本次股东大会未出现否决议案的情形; 2、本次股东大会未涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 1、会议召集人:浙江佐力药业股份有限公司(以下简称"公司"或"本公 司")董事会 2、会议召开时间:(1)现场会议召开时间:2025年5月15日(星期四)下 午14:00(2)网络投票时间:通过深圳证券交易所(以下简称"深交所")交易 系统进行网络投票的具体时间为:2025年5月15日(星期四)上午9:15—9:25,9:30 —11:30 和下午13:00—15:00;通过深交所互联网投票系统投票的具体时间为: 2025年5月15日(星期四)上午9:15至下午15:00期间的任意时间。 3、会议召开地点:浙江省德清县阜溪街道志远北路388号,浙江佐力药业股 份有限公司会议室。 4、会议召开方式:采取现场投票和网络投票相结合的方式。 5、会议主持人:公司董事长 ...
佐力药业(300181) - 关于为控股子公司向银行申请授信额度提供担保的进展公告
2025-05-09 09:22
证券代码:300181 证券简称:佐力药业 公告编号:2025-030 浙江佐力药业股份有限公司 关于为控股子公司向银行申请授信额度提供担保的 进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有 虚假记载、误导性陈述或重大遗漏。 一、担保情况概述 浙江佐力药业股份有限公司(以下简称"公司")于 2025 年 4 月 23 日召开 了第八届董事会第五次会议、第八届监事会第五次会议,审议通过了《关于为控 股子公司向银行申请授信额度提供担保的议案》,同意为控股子公司青海珠峰冬 虫夏草药业有限公司(以下简称"珠峰药业")向银行申请授信额度不超过人民 币(含)3,000 万元提供连带责任担保,担保额度自第八届董事会第五次会议审 议通过之日起 2 年内有效。上述具体内容详见公司于 2025 年 4 月 25 日在巨潮 资讯网披露的《关于为控股子公司向银行申请授信额度提供担保的公告》(公告 编号:2025-025)。 二、担保进展情况 为满足控股子公司珠峰药业日常经营发展需要,公司近日与中信银行股份有限 公司西宁分行(以下简称"中信银行西宁分行")签署了《最高额保证合同》,同 意公司为珠峰药业向中信银 ...
佐力药业(300181):业绩符合预期,百令胶囊成长可期
Changjiang Securities· 2025-05-09 06:04
丨证券研究报告丨 公司研究丨点评报告丨佐力药业(300181.SZ) [Table_Title] 业绩符合预期,百令胶囊成长可期 报告要点 [Table_Summary] 2025 年 4 月 24 日,公司发布 2024 年报及 2025 年一季报。2024 年实现营业收入 25.78 亿 元,同比增长 32.71%;实现归母净利润 5.08 亿元,同比增长 32.60%;实现扣非归母净利润 5.08 亿元,同比增长 35.89%。2025 年第一季度,公司实现营业收入 8.24 亿元,同比增长 22.52%;实现归母净利润 1.81 亿元,同比增长 27.20%;实现扣非归母净利润 1.81 亿元,同 比增长 26.16%。 分析师及联系人 [Table_Author] 彭英骐 张楠 SAC:S0490524030005 SAC:S0490524070006 SFC:BUZ392 请阅读最后评级说明和重要声明 %% %% %% %% research.95579.com 1 佐力药业(300181.SZ) cjzqdt11111 [Table_Title2] 业绩符合预期,百令胶囊成长可期 [Table_ ...
创业板公司融资余额五连降 其间累计减少56.63亿元
Core Points - The financing balance of the ChiNext board has decreased for five consecutive trading days, totaling a reduction of 5.66 billion yuan [1][2] - As of April 30, 2025, the total margin balance of the ChiNext board was 332.81 billion yuan, down by 3.24 billion yuan from the previous trading day [1][2] Financing Balance Changes - The financing balance on April 30, 2025, was 331.96 billion yuan, a decrease of 3.23 billion yuan from the previous day [2] - During the decline, 287 stocks saw an increase in financing balance, with 26 stocks increasing by over 20% [2] - The stock with the largest increase in financing balance was Bochuang Technology, which rose by 216.75% to 336 million yuan [2][3] - Conversely, 645 stocks experienced a decrease in financing balance, with 80 stocks declining by over 10% [2] - The stock with the largest decrease was Huali Group, which fell by 41.74% to 136 million yuan [2][3] Market Performance - Stocks with a financing balance increase of over 20% averaged a rise of 7.47%, outperforming the ChiNext index [5] - Notable gainers included Daye Co., Ltd. and United Chemical, which rose by 57.60% and 57.50%, respectively [5] - Major losers included Honggong Technology and Meihao Medical, which fell by 16.37% and 11.35%, respectively [5] Notable Stocks - The stocks with the largest increases in financing balance included Bochuang Technology (2.30 billion yuan increase), New Yisheng (200 million yuan), and Guiding Compass (175 million yuan) [5][6] - The stocks with the largest decreases in financing balance included Dongfang Fortune (678 million yuan decrease), Shenghong Technology (601 million yuan), and Runze Technology (295 million yuan) [5][6]
佐力药业(300181):2024年报及2025年一季报点评:核心产品稳定增长,分红率保持在较高水平
Guohai Securities· 2025-04-30 02:41
Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [1]. Core Insights - The company's core products are experiencing stable growth, with a high dividend payout ratio maintained above 80% for two consecutive years [4][6]. - In 2024, the company achieved a revenue of 2.578 billion yuan, a year-on-year increase of 32.71%, and a net profit attributable to shareholders of 508 million yuan, also up by 32.60% [4]. - For Q1 2025, the company reported a revenue of 824 million yuan, reflecting a year-on-year growth of 22.52%, and a net profit of 181 million yuan, up by 27.20% [4]. Summary by Sections Revenue and Profit Growth - The company’s core product, Wuling Mushroom Powder, is a new type of traditional Chinese medicine, contributing significantly to revenue. In 2024, the Wuling series generated 1.438 billion yuan, a growth of 17.14%, accounting for 55.79% of total revenue [6]. - The company expects revenue for 2025, 2026, and 2027 to be 3.263 billion, 4.115 billion, and 5.120 billion yuan respectively, with growth rates of 27%, 26%, and 24% [8]. Cost Management and Efficiency - The company has shown significant cost reduction and efficiency improvements, with a sales expense ratio of 32.53%, down by 7.5 percentage points year-on-year, and a management expense ratio of 4.28%, down by 0.7 percentage points [6]. Dividend Policy - The company plans to distribute a cash dividend of 415 million yuan for 2024, maintaining a dividend payout ratio exceeding 80% [6]. Earnings Forecast - The forecasted net profit for 2025, 2026, and 2027 is 662 million, 861 million, and 1.101 billion yuan respectively, with corresponding growth rates of 30% for 2025 and 2026, and 28% for 2027 [8].
杠杆资金加仓10股超亿元
盘面上,PEEK材料概念涨超2%,肯特股份(301591)、新瀚新材(301076)等涨超10%,中研股份、 富恒新材等涨超5%。 4月28日早盘,A股市场主要指数震荡走弱,钢铁、银行、电力、互联网电商等逆市涨幅居前。 超超临界发电概念涨幅居前,华电能源(600726)、华银电力(600744)、京能电力(600578)等涨 停。 10股杠杆资金加仓超1亿元 截至4月25日,市场融资余额合计1.79万亿元,较前一交易日减少54.02亿元。 具体到个股,4月25日获融资净买入千万元以上的有250只,其中10只融资净买入额超1亿元。招商蛇口 (001979)融资净买入额居首,当日净买入2.01亿元;其次是比亚迪(002594)、拓维信息 (002261),融资净买入金额分别为1.94亿元、1.72亿元;融资净买入金额居前的还有寒武纪、浙江荣 泰(603119)、佐力药业(300181)等。 | 4月25日融资净买入居前个股 | | | | | | | --- | --- | --- | --- | --- | --- | | 融资净买入 代码 | | (亿元) | 最新融资余 额(亿元) | 占流通市值 比例 ( ...
佐力药业(300181):2024年报、2025一季报点评:盈利能力稳健提升,收入及利润创单季度新高
Soochow Securities· 2025-04-27 12:34
Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's profitability is steadily improving, with revenue and profit reaching a new quarterly high [1] - The core products are showing robust growth, and the company's profit margins are being maintained despite price pressures from collective procurement [8] - The company is expected to continue its growth trajectory, particularly in the OTC market, while maintaining a high dividend payout ratio [8] Financial Performance Summary - Total revenue for 2024 is projected at 25.78 billion yuan, a year-on-year increase of 32.71% [8] - Net profit attributable to shareholders for 2024 is expected to be 5.08 billion yuan, also reflecting a 32.60% increase [8] - The earnings per share (EPS) for 2024 is forecasted to be 0.72 yuan, with a price-to-earnings (P/E) ratio of 21.99 [1][9] Product Performance Summary - The revenue from the Wuling series is expected to reach 14.38 billion yuan in 2024, with a year-on-year growth of 17.14% [8] - The Chinese herbal medicine series is projected to generate 6.73 billion yuan in revenue, marking a significant increase of 46.02% [8] - The revenue from Chinese herbal formula granules is anticipated to grow by 143.19%, reaching 1.02 billion yuan [8] Future Projections - The company’s net profit is projected to reach 6.55 billion yuan in 2025 and 8.41 billion yuan in 2026, with corresponding P/E ratios of 17 and 13 [8] - By 2027, the net profit is expected to reach 10.41 billion yuan, with a P/E ratio of 11 [1][9]
佐力药业(300181) - 2025年4月25日投资者关系活动记录表
2025-04-26 07:44
Group 1: Company Performance Overview - The company's OTC sales revenue accounts for approximately 10% of total sales, with a strategy focused on expanding the OTC market and enhancing product accessibility and repurchase rates [2] - In Q1 2025, online sales showed significant growth, although the overall online sales proportion remains low [3] - The company aims to develop the Wuling Capsule into a large-scale product with a target of 2 billion in sales, leveraging its presence in 15,000 medical institutions [4] Group 2: Sales Growth and Product Performance - The sales volume of Lingze Tablets increased by 23.17% in 2024, with Q1 2025 sales volume and revenue growing by 22.49% and 23.39% respectively [4] - The Chinese herbal medicine segment saw a 26.39% growth in Q1 2025, with the company operating over 1,000 product specifications and 180 cooperative herbal planting bases [5] - The Chinese herbal formula granules achieved a revenue of 102 million in 2024, with a 50.64% increase in Q1 2025 compared to the previous year [5] Group 3: Financial Management and Challenges - The net cash flow from operating activities significantly decreased in Q1 2025 due to increased period expenses and prepayments for raw materials [8] - Accounts receivable increased due to higher sales revenue and the growth in income from herbal formula granules and commercial circulation [9] - The company is implementing dynamic management of sales expenses, aligning spending with development stages and sales cycles [7]
浙江佐力药业股份有限公司2024年年度报告摘要
Core Viewpoint - The company has reported its annual results, highlighting its main business in pharmaceutical research, production, and sales, with a focus on traditional Chinese medicine and innovative drug development [1][2]. Company Overview - The company specializes in the research, production, and sales of pharmaceuticals, with key products including various traditional Chinese medicine formulations and innovative drugs targeting specific health conditions [2][3]. Main Products - **Wuling Capsule**: A unique product and a national class I new drug, primarily used in various medical fields for its cognitive enhancement and anxiety relief properties. It has been included in 80 clinical guidelines and expert consensus documents [2][3]. - **Lingze Tablet**: An innovative drug for benign prostatic hyperplasia, recognized for its unique mechanism of action and included in 12 clinical guidelines [3]. - **Linglianhua Granules**: A product aimed at alleviating menopausal symptoms, now classified as a non-prescription drug and recommended in clinical guidelines [4]. - **Bailing Tablet and Capsule**: Both products are used for respiratory and renal conditions, with significant clinical research supporting their efficacy in chronic obstructive pulmonary disease and chronic kidney disease [4][5]. - **Psyllium Calcium Tablet**: A first generic drug for irritable bowel syndrome, recommended in multiple clinical guidelines for its safety and efficacy in treating constipation [5]. Financial Data and Shareholder Information - The company has undergone a change in its accounting firm, now audited by Zhonghui Accounting Firm, and has proposed a cash dividend of 6.00 yuan per 10 shares [1]. - As of the report date, the company has a total of 14,895,074 shares held in its repurchase account, representing 2.12% of the total share capital [8]. Important Events - The company received a drug registration certificate for Bailing Capsule from the National Medical Products Administration [9]. - The company has adjusted the timeline for several fundraising investment projects, including the construction of an intelligent traditional Chinese medicine production base [10]. - A strategic cooperation framework agreement was signed with Lingyi (Hangzhou) Biotechnology Co., Ltd. to enhance collaboration in the pharmaceutical sector [14].